Positron Emission Tomography in Prostate Cancer
- Registration Number
- NCT00121212
- Lead Sponsor
- Washington University School of Medicine
- Brief Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
...
- Detailed Description
The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 179
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Surgery - Positive PET scan carbon-11 acetate PET scan If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy. Radiation therapy Negative or Positive PET scan carbon-11 acetate PET scan If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence. Surgery - Negative PET scan carbon-11 acetate PET scan If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
- Primary Outcome Measures
Name Time Method Determine the role of AC-PET in changing initial patient management Completion of patient treatment
- Secondary Outcome Measures
Name Time Method Determine the value of AC-PET in predicting recurrence Minimum of 2 years and maximum of 5 years Assess the performance of AC-PET for detection of lymph node metastasis by comparison with biopsy. Minimum of 2 years and maximum of 5 years
Trial Locations
- Locations (1)
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
🇺🇸Saint Louis, Missouri, United States